Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2025)

Sutro Biopharma has disclosed Cash & Equivalents across 10 years of filings, most recently posting $58.1 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $58.1 million, down 69.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $58.1 million (down 69.45% YoY), and the FY2025 annual result was $58.1 million, down 69.45% from the prior year.
• Cash & Equivalents came in at $58.1 million for Q4 2025 at Sutro Biopharma, down from $65.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $235.1 million in Q2 2023 to a low of $28.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $65.6 million (2024), against an average of $84.5 million.
• Across the five-year window, Cash & Equivalents plunged 85.25% in 2021 and jumped 215.17% in 2022, its largest moves.
• Sutro Biopharma's Cash & Equivalents stood at $30.4 million in 2021, then jumped by 55.37% to $47.3 million in 2022, then jumped by 46.59% to $69.3 million in 2023, then surged by 174.74% to $190.3 million in 2024, then slumped by 69.45% to $58.1 million in 2025.
• The last three Cash & Equivalents figures came in at $58.1 million (Q4 2025), $65.9 million (Q3 2025), and $64.0 million (Q2 2025), per Business Quant data.